Retrophin Recognizes Rare Disease Day 2020 and the Importance of Working Together Toward More Equitable Access to Care
February 28, 2020 08:00 ET
|
Retrophin, Inc.
SAN DIEGO, Feb. 28, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) will join the National Organization for Rare Disorders (NORD), the European Organisation for Rare Diseases (EURORDIS), and...
Retrophin to Report Fourth Quarter and Full Year 2019 Financial Results
February 10, 2020 16:30 ET
|
Retrophin, Inc.
SAN DIEGO, Feb. 10, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced it will report fourth quarter and full year 2019 financial results on Monday, February 24, 2020 after the...
Retrophin Provides Corporate Update and 2020 Outlook
January 13, 2020 06:59 ET
|
Retrophin, Inc.
SAN DIEGO, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that, based on preliminary and unaudited financial data, the Company expects net product sales for the...
Retrophin to Report Third Quarter 2019 Financial Results
October 16, 2019 16:30 ET
|
Retrophin, Inc.
SAN DIEGO, Oct. 16, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced it will report third quarter 2019 financial results on Wednesday, October 30, 2019 after the close of the...
Retrophin Reports Second Quarter 2019 Financial Results
August 06, 2019 16:01 ET
|
Retrophin, Inc.
Top-line results from pivotal Phase 3 FORT Study in PKAN on-track for 3Q 2019 Commercial launch for THIOLA® EC underway following FDA-approval for the treatment of cystinuria Second quarter revenues...